Beijing Strong Biotechnologies Inc
Beijing Strong Biotechnologies,Inc. researches, develops, manufactures, and sells in-vitro diagnostics (IVD) products and services in China and internationally. The company offers biochemistry reagents, including liver, renal, lipid, cardiac, diabetes, special protein, tumor marker, pancreas, inorganic, inflammation, TDM, and other panels; and coagulation products, such as prothrombin time, activ… Read more
Beijing Strong Biotechnologies Inc (300406) - Net Assets
Latest net assets as of September 2025: CN¥4.00 Billion CNY
Based on the latest financial reports, Beijing Strong Biotechnologies Inc (300406) has net assets worth CN¥4.00 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.30 Billion) and total liabilities (CN¥1.30 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.00 Billion |
| % of Total Assets | 75.45% |
| Annual Growth Rate | 22.72% |
| 5-Year Change | 20.72% |
| 10-Year Change | 251.67% |
| Growth Volatility | 30.19 |
Beijing Strong Biotechnologies Inc - Net Assets Trend (2011–2024)
This chart illustrates how Beijing Strong Biotechnologies Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Beijing Strong Biotechnologies Inc (2011–2024)
The table below shows the annual net assets of Beijing Strong Biotechnologies Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.13 Billion | +11.05% |
| 2023-12-31 | CN¥3.72 Billion | +13.85% |
| 2022-12-31 | CN¥3.27 Billion | +12.20% |
| 2021-12-31 | CN¥2.91 Billion | -14.90% |
| 2020-12-31 | CN¥3.42 Billion | +73.70% |
| 2019-12-31 | CN¥1.97 Billion | +15.79% |
| 2018-12-31 | CN¥1.70 Billion | +11.25% |
| 2017-12-31 | CN¥1.53 Billion | +10.23% |
| 2016-12-31 | CN¥1.39 Billion | +18.11% |
| 2015-12-31 | CN¥1.18 Billion | +19.07% |
| 2014-12-31 | CN¥987.03 Million | +107.23% |
| 2013-12-31 | CN¥476.31 Million | +23.50% |
| 2012-12-31 | CN¥385.67 Million | +33.61% |
| 2011-12-31 | CN¥288.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Strong Biotechnologies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2887.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.79 Billion | 67.41% |
| Common Stock | CN¥588.33 Million | 14.22% |
| Other Comprehensive Income | CN¥472.03 Million | 11.41% |
| Other Components | CN¥288.49 Million | 6.97% |
| Total Equity | CN¥4.14 Billion | 100.00% |
Beijing Strong Biotechnologies Inc Competitors by Market Cap
The table below lists competitors of Beijing Strong Biotechnologies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Krispy Kreme Inc
NASDAQ:DNUT
|
$317.96 Million |
|
CIR S.p.A. - Compagnie Industriali Riunite
F:BN7
|
$318.19 Million |
|
Aclaris Therapeutics Inc
NASDAQ:ACRS
|
$318.20 Million |
|
Tianjin Saixiang Technology Co Ltd
SHE:002337
|
$318.26 Million |
|
Jiangsu Rutong Petro-Machinery
SHG:603036
|
$317.90 Million |
|
Everlight Chemical Industrial Corp
TW:1711
|
$317.86 Million |
|
First Foundation Inc.
NYSE:FFWM
|
$317.81 Million |
|
BFI Finance Indonesia Tbk
JK:BFIN
|
$317.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Strong Biotechnologies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,724,591,909 to 4,138,374,136, a change of 413,782,227 (11.1%).
- Net income of 532,635,354 contributed positively to equity growth.
- Dividend payments of 124,192,060 reduced retained earnings.
- Share repurchases of 44,658,967 reduced equity.
- Other comprehensive income increased equity by 294,731,068.
- Other factors decreased equity by 244,733,168.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥532.64 Million | +12.87% |
| Dividends Paid | CN¥124.19 Million | -3.0% |
| Share Repurchases | CN¥44.66 Million | -1.08% |
| Other Comprehensive Income | CN¥294.73 Million | +7.12% |
| Other Changes | CN¥-244.73 Million | -5.91% |
| Total Change | CN¥- | 11.11% |
Book Value vs Market Value Analysis
This analysis compares Beijing Strong Biotechnologies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.79x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 17.65x to 1.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.71 | CN¥12.51 | x |
| 2012-12-31 | CN¥0.96 | CN¥12.51 | x |
| 2013-12-31 | CN¥1.19 | CN¥12.51 | x |
| 2014-12-31 | CN¥4.73 | CN¥12.51 | x |
| 2015-12-31 | CN¥4.70 | CN¥12.51 | x |
| 2016-12-31 | CN¥2.76 | CN¥12.51 | x |
| 2017-12-31 | CN¥3.08 | CN¥12.51 | x |
| 2018-12-31 | CN¥3.23 | CN¥12.51 | x |
| 2019-12-31 | CN¥3.93 | CN¥12.51 | x |
| 2020-12-31 | CN¥5.98 | CN¥12.51 | x |
| 2021-12-31 | CN¥4.89 | CN¥12.51 | x |
| 2022-12-31 | CN¥5.56 | CN¥12.51 | x |
| 2023-12-31 | CN¥6.26 | CN¥12.51 | x |
| 2024-12-31 | CN¥6.99 | CN¥12.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Strong Biotechnologies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.87%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 32.11%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.35x
- Recent ROE (12.87%) is below the historical average (19.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 34.91% | 36.52% | 0.87x | 1.10x | CN¥71.92 Million |
| 2012 | 35.53% | 36.04% | 0.88x | 1.12x | CN¥98.44 Million |
| 2013 | 37.92% | 40.63% | 0.85x | 1.09x | CN¥133.01 Million |
| 2014 | 21.34% | 41.44% | 0.49x | 1.06x | CN¥111.94 Million |
| 2015 | 20.85% | 43.28% | 0.45x | 1.07x | CN¥127.52 Million |
| 2016 | 19.57% | 40.70% | 0.45x | 1.06x | CN¥132.84 Million |
| 2017 | 17.85% | 39.34% | 0.39x | 1.16x | CN¥120.15 Million |
| 2018 | 17.66% | 38.84% | 0.42x | 1.10x | CN¥130.45 Million |
| 2019 | 16.83% | 39.44% | 0.39x | 1.09x | CN¥134.55 Million |
| 2020 | 3.51% | 13.24% | 0.21x | 1.24x | CN¥-207.48 Million |
| 2021 | 14.11% | 25.36% | 0.37x | 1.50x | CN¥118.21 Million |
| 2022 | 11.89% | 25.75% | 0.33x | 1.41x | CN¥61.98 Million |
| 2023 | 14.06% | 30.07% | 0.34x | 1.39x | CN¥151.28 Million |
| 2024 | 12.87% | 32.11% | 0.30x | 1.35x | CN¥118.80 Million |
Industry Comparison
This section compares Beijing Strong Biotechnologies Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,885,407,783
- Average return on equity (ROE) among peers: 4.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Strong Biotechnologies Inc (300406) | CN¥4.00 Billion | 34.91% | 0.33x | $317.93 Million |
| Berry Genomics Co Ltd (000710) | $108.87 Million | -46.67% | 1.22x | $377.87 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.14 Billion |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $308.32 Million | 33.58% | 0.53x | $283.14 Million |
| Maccura Biotechnology Co Ltd (300463) | $4.54 Billion | 21.06% | 0.45x | $576.46 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $4.05 Billion | -16.18% | 0.14x | $319.65 Million |
| BGI Genomics Co Ltd (300676) | $4.25 Billion | 9.09% | 0.23x | $1.45 Billion |
| Amoy Diagnostics Co Ltd (300685) | $307.91 Million | 21.77% | 0.15x | $834.75 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.82 Billion | -6.01% | 0.44x | $226.85 Million |
| SMO ClinPlus Co. Ltd. (301257) | $1.08 Billion | 12.47% | 0.26x | $347.98 Million |